Filtered By:
Condition: Autoimmune Disease
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 154 results found since Jan 2013.

Contemporary Monoclonal Antibody Utilization in Glomerular Diseases
Mayo Clin Proc Innov Qual Outcomes. 2023 Jun 30;7(4):276-290. doi: 10.1016/j.mayocpiqo.2023.04.009. eCollection 2023 Aug.ABSTRACTTherapeutic monoclonal antibodies (MAbs) have been one of the fastest growing drug classes in the past 2 decades and are indicated in the treatment of cancer, autoimmune disorders, solid organ transplantation, and glomerular diseases. The Food and Drug Administration has approved 100 MAbs between 1986 and 2021, and MAbs account for 20% of Food and Drug Administration's new drug approval every year. MAbs are preferred over traditional immunosuppressive agents because of their high specificity, red...
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Iyad Mansour Sangeetha Murugapandian Bekir Tanriover Bijin Thajudeen Source Type: research

Immunogenicity of COVID ‐19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta‐analysis
AbstractCOVID-19 vaccines approved by the Food and Drug Administration have been studied mainly in healthy individuals and there is limited information on their immunogenicity in patients with autoimmune diseases. Therefore, the current systematic review and meta-analysis study, aimed to comprehensively investigate the immunogenicity of these vaccines in patients with autoimmune inflammatory rheumatoid diseases (AIRDs). A comprehensive literature search was performed on various databases, including Google Scholar, PubMed, Web of Science, EMBASE, and Cochrane Library, to select cohort and randomized clinical trial (RCT) stu...
Source: International Journal of Rheumatic Diseases - June 13, 2023 Category: Rheumatology Authors: Maysoon Al ‐Haideri, Talar Ahmad Merza Mohammad, Shahram Darvishzadehdeldari, Zahra Karbasi, Mina Alimohammadi, Fatemeh Faramarzi, Sahar Khorasani, Ashkan Rasouli, Safa Tahmasebi, Mohammad Darvishi, Reza Akhavan‐Sigari Tags: REVIEW Source Type: research

Vaccines prevent reinduction of rheumatoid arthritis symptoms in collagen-induced arthritis mouse model
This study can pave the way for the development of flare-up mouse models and antigen-specific drug treatments.PMID:36971998 | DOI:10.1007/s13346-023-01333-8
Source: Cell Research - March 27, 2023 Category: Cytology Authors: Abhirami Thumsi Srivatsan J Swaminathan Joslyn L Mangal Abhirami P Suresh Abhinav P Acharya Source Type: research

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
Turk J Gastroenterol. 2023 Feb;34(2):89-100. doi: 10.5152/tjg.2023.22239.ABSTRACTPrimary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-a...
Source: The Turkish Journal of Gastroenterology - February 27, 2023 Category: Gastroenterology Authors: Romelia Barba Bernal Bryan Ferrigno Esli Medina Morales Cristina M Castro Daniela Goyes Hirsh Trivedi Vilas R Patwardhan Alan Bonder Source Type: research

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
Recent studies have suggested that dipeptidyl peptidase 4 (DPP4) inhibitors increase the risk of development of bullous pemphigoid (BP), which is the most common autoimmune blistering skin disease; however, the associated mechanisms remain unclear, and thus far, no therapeutic targets responsible for drug-induced BP have been identified. Therefore, we used clinical data mining to identify candidate drugs that can suppress DPP4 inhibitor-associated BP, and we experimentally examined the underlying molecular mechanisms using human peripheral blood mononuclear cells (hPBMCs). A search of the US Food and Drug Administration Ad...
Source: Frontiers in Immunology - January 5, 2023 Category: Allergy & Immunology Source Type: research

B cell-targeted therapies in systemic lupus erythematosus
J Autoimmun. 2022 Aug 10:102873. doi: 10.1016/j.jaut.2022.102873. Online ahead of print.ABSTRACTSystemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology that primarily affects women of childbearing age. There is no disease more heterogeneous than SLE as patients experience a myriad of manifestations and unpredictable periods of heightened disease activity. This heterogeneity not only makes it difficult for treatment decisions and prognostication, but has made drug development quite challenging. Despite these challenges, belimumab, voclosporin, and anifromulab, approved by the United States Foo...
Source: Journal of Autoimmunity - August 13, 2022 Category: Allergy & Immunology Authors: Leah Arbitman Richard Furie Himanshu Vashistha Source Type: research